- Home
- BATL vs CASI Comparison
BATL vs CASI Comparison
Compare BATL & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BATL | CASI |
|---|---|---|
| Founded | 1987 | 1991 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 19.7M |
| IPO Year | 2004 | 2023 |
Fundamental Metrics
Financial Performance| Metric | BATL | CASI |
|---|---|---|
| Price | $4.13 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 6.9M | 18.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $193,893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.74 |
| 52 Week High | $6.89 | $3.08 |
Technical Indicators
Market Signals| Indicator | BATL | CASI |
|---|---|---|
| Relative Strength Index (RSI) | 66.72 | 39.49 |
| Support Level | $2.33 | $0.74 |
| Resistance Level | $3.33 | $0.97 |
| Average True Range (ATR) | 0.64 | 0.09 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 59.94 | 19.03 |
Price Performance
Historical ComparisonAbout BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.